1. Fan Wu#, Yi-Yun Yin#, Wen-Hua Fan#,You Zhai#, Ming-Chen Yu, Di Wang, Chang-Qing Pan, Zheng Zhao, Guan-Zhang Li, Wei Zhang*..Immunological profiles of human oligodendrogliomas define two distinct molecular subtypes.EBioMedicine.2023.1.87:104410.SCI |
2. Chen Wang#, Mingchen Yu#, Wei Zhang*..Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.Cancer Letters.2022.12(1).550:215945.SCI |
3. Li G#, Li L#, Li Y, Qian Z, Wu F, He Y, Jiang H, Li R, Wang D, Zhai Y, Wang Z, Jiang T, Zhang J*, Zhang W*..An MRI radiomics approach to predict survival and tumor infiltrating macrophages in gliomas.Brain.2022.6.awab340.SCI |
4. Li G#, Huang R#, Fan W, Wang D, Wu F, Zeng F, Yu M, Zhai Y, Chang Y, Pan C, Jiang T, Yan W*, Wang H*, Zhang W*..Clinical Characterization and Immunosuppressive Regulation of CD161 (KLRB1) in Glioma through 916 Samples.Cancer Science.2022.113(2).756-769.SCI |
5. Wu F#, Liu YW#, Li GZ#, Zhai Y, Feng YM, Ma WP, Zhao Z, Zhang W*..Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes.British journal of cancer.2021.125(2).255-264.SCI |
6. Pan C#, Zhai Y, Li G, Jiang T*, Zhang W*..NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas.Frontiers in oncology.2021.11.751183.SCI |
7. Wang D#, Jiang H#, Wang Z, Huang R, Jiang T, Kahlert UD*, Li G*, Zhang W*..Functional Clustering Analysis Identifies Specific Subtypes of Aldehyde Dehydrogenase Associated with Glioma Immunity.Translational cancer research.2021.10(12).5052-5064.SCI |
8. Li G#, Huang R#, Fan W#, Wang D#, Wu F, Zeng F, Yu M, Zhai Y, Chang Y, Pan C, Jiang T, Yan W*, Wang H*, Zhang W*..Galectin-9 TIM-3 as a key regulator of immune response in gliomas with chromosome 1p 19q codeletion.Frontiers in Immunology.2021.12.800928.SCI |
9. Xiao Z#, Zhang W#, Li G#, Li W, Li L, Sun T, He Y, Liu G, Wang L, Han X, Wen H, Liu Y, Chen Y, Wang H, Li J, Fan Y*, Zhang J*..Multiomics Analysis Reveals the Prognostic Non-tumor Cell Landscape in Glioblastoma Niches.Frontiers in Genetics.2021.12.741325.SCI |
10. Chang Y#, Huang R#, Zhai Y, Huang L, Feng Y, Wang D, Chai R, Zhang W*, Hu H*..A potentially effective drug for patients with recurrent glioma: sermorelin.Annals of Translational Medicine.2021.9(5).406.SCI |
11. Feng Y#, Li G#, Shi Z, Yan X, Li R, Zhai Y, Chang Y, Wang D, Kahlert UD, Zhang W*, Yuan F*..Uronic acid metabolic process-related gene expression-based signature predicts overall survival of glioma.BIOSCIENCE REPORTS.2021.41(1).BSR20203051.SCI |
12. Sun T#, He Y#, Li W#, Liu G, Li L, Wang L, Xiao Z, Han X, Wen H, Liu Y, Chen Y, Wang H, Li J, Fan Y, Zhang W*, Zhang J*..neoDL: a novel neoantigen intrinsic feature-based deep learning model identifies IDH wild-type glioblastomas with the longest survival.BMC Bioinformatics.2021.22(1).382.SCI |
13. Zhang W#, Zhai Y, Li G, Jiang T*. .A novel gene signature based on five immune checkpoint genes predicts the survival of glioma.Chin Neurosurg J..2021.7(1).15.SCI |
14. Li G#, Wu F, Zeng F, Zhai Y, Feng Y, Chang Y, Wang D, Jiang T*, Zhang W*..A novel DNA repair-related nomogram predicts survival in low-grade gliomas.CNS Neuroscience & Therapeutics.2020.27(2).186-195.SCI |
15. Jiang T*, Nam DH*, Ram Z*, Poon WS*, Wang J*, Boldbaatar D*, et al..Clinical practice guidelines for the management of adult diffuse gliomas.Cancer Letters.2020.6(20).0304-3835.SCI |
16. Feng Y#, Li G#, Shi Z, Yan X, Wang Z, Jiang H, Chen Y, Li R, Zhai Y, Chang Y, Zhang W*, Yuan F*..A novel methylation signature predicts radiotherapy sensitivity in glioma.Scientific Reports.2020.10(1).20406.SCI |
17. Herrera-Rios D#, Li G#, Khan D, Tsiampali J, Nickel AC, Aretz P, Hewera M, Suwala AK, Jiang T, Steiger HJ, Kamp MA, Muhammad S, Hänggi D, Maciaczyk J, Zhang W*, Kahlert UD*..A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma.Scientific Reports.2020.10(1).16218.SCI |
18. Li G#, Zhai Y#, Liu H, Wang Z, Huang R, Jiang H, Feng Y, Chang Y, Wu F, Zeng F, Jiang T*, Zhang W*..RPP30, a transcriptional regulator, is a potential pathogenic factor in glioblastoma.Aging (Albany NY).2020.12(16).16155-16171.SCI |
19. Chang Y#, Li G#, Zhai Y, Huang L, Feng Y, Wang D, Zhang W*, Hu H*..Redox Regulator GLRX Is Associated With Tumor Immunity in Glioma.Frontiers in Immunology.2020.30(11).580934.SCI |
20. Li G#, Zhai Y, Wang Z, Wang Z, Huang R, Jiang H, Li R, Feng Y, Chang Y, Jiang T*, Zhang W*..Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages.Cancer Medicine.2020.9(6).1955-1965.SCI |
21. Wang Z#, Zhong L#, Li G, Huang R, Wang Q, Wang Z, Zhang C, Chen B, Jiang T*, Zhang W*..Pre-treatment neutrophils count as a prognostic marker to predict chemotherapeutic response and survival outcomes in glioma: a single-center analysis of 288 cases.American Journal of Translational Research.2020.12(1).90-104.SCI |
22. Wu F#, Wang ZL, Wang KY, Li GZ, Chai RC, Liu YQ, Jiang HY, Zhai Y, Feng YM, Zhao Z, Zhang W*..Classification of diffuse lower-grade glioma based on immunological profiling.Molecular Oncology.2020.14(9).2081-2095.SCI |
23. Zhai Y#, Li G#, Li R, Chang Y, Feng Y, Wang D, Wu F*, Zhang W*..Single-Cell RNA-Sequencing Shift in the Interaction Pattern Between Glioma Stem Cells and Immune Cells During Tumorigenesis.Frontiers in Immunology.2020.8(11).581209.SCI |
24. Wu F#, Li GZ#, Liu HJ, Zhao Z, Chai RC, Liu YQ, Jiang HY, Zhai Y, Feng YM, Li RP, Zhang W*..Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.JOURNAL OF PATHOLOGY.2020.251(3).272-283.SCI |
25. Li GZ#, Zhang KN#, Wang Z, Hu HM, Wang ZL, Huang RY, Jiang HY, Zhai Y, Feng YM, Chang YH, Li RP, Wu F, Zeng F, Jiang T*, Zhang W*..Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy.OncoTargets and Therapy.2019.12.10263-10273.SCI |
26. Zhai Y#, Li G, Jiang T, Zhang W*..CAR-armed cell therapy for gliomas.American Journal of Translational Research.2019.9(12).2554-2566.SCI |
27. Guanzhang Li#, Yiming Li, Xing Liu#, Zheng Wang, Chuanbao Zhang, Fan Wu, Haoyu Jiang, Wenlong Zhang, Zhaoshi Bao, Yongzhi Wang, Jinquan Cai, Liang Zhao, Ulf D. Kahlert, Tao Jiang, Wei Zhang*..ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma.Cell Death & Disease.2018.9(12).1190.SCI |
28. Shi Y#, Guryanova OA#, Zhou W#, Liu C, Huang Z, Fang X, Wang X, Chen C, Wu Q, He Z, Wang W, Zhang W, Jiang T, Liu Q, Chen Y, Wang W, Wu J, Kim L, Gimple RC, Feng H, Kung HF, Yu JS, Rich JN, Ping YF, Bian XW*, Bao S*..Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance.Science Translational Medicine.2018.10(443).pii: eaah6816.SCI |
29. Li G#, Wang Z#, Zhang C, Liu X, Yang F, Sun L, Liang J, Hu H, Liu Y, You G, Bao Z, Zhang W, Wang Z, Jiang T*..MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status.Disease Markers.2018.2018.5975216.SCI |
30. Wang Z#, Liu X#, Wang Z, Bao Z, Zhang W, Zhang C, Jiang T*..Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.Current Molecular Medicine.2018.17(7).518-526.SCI |
31. Wang Z#, Yang P#, You G, Zhang W, Bao ZS, Jiang T*, Zhang CB*..Predicting the likelihood of postoperative seizure status based on mRNA sequencing in low-grade gliomas.Future Oncology.2018.14(6).545-552.SCI |
32. Hu H#, Mu Q#, Bao Z#, Chen Y#, Liu Y#, Chen J, Wang K, Wang Z, Nam Y, Jiang B, Sa JK, Cho HJ, Her NG, Zhang C, Zhao Z, Zhang Y, Zeng F, Wu F, Kang X, Liu Y, Qian Z, Wang Z, Huang R, Wang Q, Zhang W, Qiu X, Li W, Nam DH, Fan X*, Wang J*, Jiang T*..Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.Cell.2018.175(6).1665-1678.SCI |
33. Li G* ,Wang Z*,Zhang C*,Liu X* Cai J,Wang Z,Hu H,Wu F,Bao Z,Liu Y,Zhao L,Liang T,Yang F,Huang R,Zhang W*,Jiang T*..Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.Oncoimmunology .2017.6(8).e1328339.SCI |
34. Wang Z#, Zhang CB#, Liu X, Wang ZL, Sun LH, Li GZ, Liang JS, Hu HM, Liu YW, Zhang W*, Jiang T*.. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.Oncoimmunology.2016.5(11).e1196310.SCI |
35. Cai J#, Zhang W#, Yang P#, Wang Y, Li M, Zhang C, Wang Z, Hu H, Liu Y, Li Q1, Wen J, Sun B, Wang X, Jiang T*, Jiang C*..Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance.PLOS ONE.2015.10(5).e0126022.SCI |